Swiss National Bank Raises Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Swiss National Bank grew its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 3.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 108,600 shares of the company’s stock after acquiring an additional 3,500 shares during the quarter. Swiss National Bank owned about 0.11% of Dyne Therapeutics worth $2,559,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in DYN. FMR LLC boosted its holdings in Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after purchasing an additional 3,707,734 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Dyne Therapeutics by 47.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after buying an additional 2,189,339 shares during the last quarter. State Street Corp boosted its stake in shares of Dyne Therapeutics by 13.8% in the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after buying an additional 440,890 shares during the last quarter. RTW Investments LP grew its holdings in shares of Dyne Therapeutics by 6.8% in the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after acquiring an additional 431,503 shares during the period. Finally, RA Capital Management L.P. increased its position in Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after acquiring an additional 331,940 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 6,237 shares of company stock worth $77,760 over the last 90 days. Corporate insiders own 20.77% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of DYN opened at $11.80 on Friday. The firm has a market cap of $1.33 billion, a P/E ratio of -3.31 and a beta of 1.11. Dyne Therapeutics, Inc. has a 1 year low of $10.72 and a 1 year high of $47.45. The company has a 50 day simple moving average of $13.33 and a two-hundred day simple moving average of $23.66.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Robert W. Baird started coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company. Finally, JPMorgan Chase & Co. decreased their target price on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.46.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.